PharmaNanoGene: Farmacocinética, Nanotecnología y Terapia Génica
Novartis (Sweden)
Täby, SueciaNovartis (Sweden)-ko ikertzaileekin lankidetzan egindako argitalpenak (1)
1998
-
The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A: Implications for drug-drug interactions and pharmacological activity of the main metabolite
Drug Metabolism and Disposition, Vol. 26, Núm. 8, pp. 802-811